This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Daclatasvir (Daklinza™) and asunaprevir (Sunpreva™)! Competition is healthy and could help lower prices of new hepatitis C treatments! HepCBC has been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE and RIBAVIRIN-FREE 2-drug combo asunaprevir (Sunvepra™) and daclatasvir (Daklinza™) which was developed for Chronic Hepatitis C by pharmaceutical company, Bristol-Myers Squibb. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination). Patients’ CAREGIVERS are also encouraged to reply.
-
For background info go to http://hepcbc.bchep.org/bms-daclatasvir-and-asunaprevir-background-info/ .
-
For the actual questionnaire, go to: http://hepcbc.bchep.org/questions-cadth-bms-2-drug/.
DEADLINE: Tuesday, February 24 (midnight). Send your answers via email or email attached Word file to (spam-proof email address): office DOT hepcbc AT gmail DOT com. -
Please tweet, re-tweet, put on Facebook, and forward this request throughout your network; thanks!
*CADTH = Canadian Agency for Drugs and Technologies in Health, which does government-requested reviews for Health Canada and the Canadian Drug Review process.